Example: dental hygienist

2019 Global life sciences outlook Focus and transform ...

2019 Global life sciences outlook Focus and transform | Accelerating change in life sciences 2019 Global life sciences outlook l Focus and transform | Accelerating change in life sciences Contents outlook 3. Economic overview 4. Focus 12. transform 23. Questions/actions leaders should consider for 2019 39. Appendix 41. Endnotes 43. Contacts 53. 2. 2019 Global life sciences outlook | Focus and transform | Accelerating change in life sciences outlook 2019 will continue to see a Focus on digital transformation in life sciences . This transformation is about using technology symbiotically and strategically, not just adopting a particular technology or device. Data is fast becoming the currency of life sciences , and digital enterprises are building a new business model for the In 2019, how can leaders move forward and accelerate change in life sciences ?

2019 Global life sciences outlook Focus and transform | Accelerating change in life sciences 5 Regional and country outlooks, 2018–2022 Regionally, transition economies 9 are expected to …

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of 2019 Global life sciences outlook Focus and transform ...

1 2019 Global life sciences outlook Focus and transform | Accelerating change in life sciences 2019 Global life sciences outlook l Focus and transform | Accelerating change in life sciences Contents outlook 3. Economic overview 4. Focus 12. transform 23. Questions/actions leaders should consider for 2019 39. Appendix 41. Endnotes 43. Contacts 53. 2. 2019 Global life sciences outlook | Focus and transform | Accelerating change in life sciences outlook 2019 will continue to see a Focus on digital transformation in life sciences . This transformation is about using technology symbiotically and strategically, not just adopting a particular technology or device. Data is fast becoming the currency of life sciences , and digital enterprises are building a new business model for the In 2019, how can leaders move forward and accelerate change in life sciences ?

2 They should Focus and transform . Focus on patients and regulators as partners, building partnerships that are strategic and relationship-driven Focus on external innovation and expanding a richly networked ecosystem Focus on mobilizing data and collaborating with nontraditional partners like startups and tech giants Focus on outsourcing for advanced technologies and manufacturing capabilities, and choosing vendors who share similar values and risk profiles Transforming means aligning the enterprise to deliver an exceptional customer and patient experience, using data intelligence to create value, and evolving a digital culture and new leadership styles. While this type of change may be challenging, it is likely to be essential to accelerating change in the year 3.

3 2019 Global life sciences outlook | Focus and transform | Accelerating change in life sciences Economic overview Global health spending is on the rise. The Growth trends US$900 billion in 2019 to US$ trillion compound annual growth rate (CAGR) for by 2024. From 2018 to 2024, CAGR for Life expectancy health care spending across 60 countries pharmaceutical drugs is expected to be is predicted to increase percent for the Overall, life expectancy at birth is rising percent, or six times the percent over period 2018 2022, compared to just rapidly and expected to reach years 2011 Drivers of growth are predicted percent over 2013 2017. The overall share by 2022, up from in 2017.

4 Falling infant to be novel therapies that address key, of Gross Domestic Product (GDP) devoted mortality is contributing to most of the unmet needs and increased access to to health is forecast at percent for However, the US Centers for Disease medicines, as a result of new pricing policies 2019. Per-person spending varies widely Control and Prevention (CDC) reports that around the world. by country from US$11,674 in the US to life expectancy in the United States fell for Challenges to growth include payer scrutiny, just US$54 in Pakistan. Except for North the third year in a row, to sales losses due to genericization, and America, all regions anticipate spending to Pharmaceutical drug and disease trends competition from biosimilars.

5 In 2019, it is accelerate compared to the growth over the estimated that US$19 billion in prescription period 2013 Global pharmaceutical spending is sales may be at risk due to patent expiries, predicted to outpace overall health with approximately half resulting in lost care Worldwide prescription drug sales are expected to rise from Figure 1. Worldwide prescription drug sales, 2018 2024. 1400. 1200. + CAGR 2018 24. 1000. 800. 600. 828. 749 785. 663 706. 583 608 631. 400 590 572 569 581 565 576. 558. 262. 240. 216. 200 192. 151 169. 125 138. 94 100 112. 69 77 82 88. 100 104 109 114. 67 70 76 78 80 81 84 89 95. 60 66. 0. 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024.

6 Prescription excl. Generics & Orphan Orphan Generics Source: EvaluatePharma, 2018. 4. 2019 Global life sciences outlook | Focus and transform | Accelerating change in life sciences Regional and country outlooks, United Kingdom: A major exporter of India: The world's tenth-largest 2018 2022 pharmaceutical products. Pharmaceutical pharmaceutical market in US-dollar terms. sales are up percent annually. Private expenditure is expected to drive Regionally, transition economies9 are However, continued uncertainty around growth. In particular, the increased use of expected to be the fastest-growing market, Brexit throughout 2019 may disrupt online pharmacies is creating a demand for averaging percent per year, with the trade.

7 Pharmaceutical sales in the United more advanced, costly medicines among highest growth expected in the Ukraine Kingdom are expected to rise at a CAGR India's growing middle class. NCDs account at percent CAGR in US-dollar terms. of 4 percent in nominal local-currency for 53 percent of deaths, while diabetes Latin America is likely to be the slowest at Age-related diseases, including accounts for only 2 percent. The leading percent growth per year. North America dementia, (especially Alzheimer's), cause of death is ischemic heart disease is expected to remain the largest regional Parkinson's, rheumatism, osteoporosis, followed by chronic obstructive pulmonary, market, averaging percent growth per and metabolic disorders are on the rise, diarrheal, and cerebrovascular year, but will see a fall in its share of total and the UK's obesity rate is among the pharmaceutical spending to percent Pharmaceutical Research &.

8 Highest in Europe. The number of people by Development (R&D). with diabetes is expected to reach million by 2025, from million in 2016, with Worldwide pharmaceutical R&D spend is United States: While pharmaceutical cancer and circulatory system diseases being expected to decrease from percent spending is expected to rise at a CAGR. the leading causes of death in England and CAGR in 2018 to percent in 2019. of percent over the forecast period, Companies may improve R&D efficiencies by a sharp deceleration may be expected using big data and predictive analytics, or by by 2020 in anticipation of a possible China: Pharmaceutical sales are expected directing less revenue toward replenishing cyclical downturn in the US economy and to see a CAGR of percent in nominal pipelines.

9 Overall, R&D spend from pharma continued political uncertainty. In 2019, local-currency terms. Central government and biotech companies is expected to be Americans without health insurance will reforms represent a maturation of the US$177 billion in 2019, compared to about not face a penalty, and private insurers market,20 and the recent expansion of US$171 billion in may shift their Focus to younger and drug reimbursement lists is expected healthier clients and low-cost policies. According to Deloitte's annual study, to fuel demand. In the next year, there It is predicted that the public sector Measuring the returns from pharmaceutical will likely be continued concerns around will struggle to cover costly care for the innovation, projected R&D returns for corruption and safety as a result of elderly and low-income Heart 12 large cap biopharma companies, have recent drug However, evolving disease and cancer are the leading causes fallen to their lowest level in nine years, invoicing systems are being designed of death in the United at percent in 2018, down from to streamline distribution channels and percent in 2010.

10 The cost to bring an asset prevent Noncommunicable Japan: The second-largest pharmaceutical to market has increased to record levels in diseases (NCDs) account for 85 percent market after the United States. Its aging 2018 (to US$ million) but the forecast of deaths. Other leading causes of death population is expected to continue to peak sales per asset have more than halved are cerebrovascular disease, ischemic drive demand for drugs to treat cancer, since 2010 (from US$816 million in 2010 to heart disease, chronic obstructive diabetes, cardiovascular disease, and US$407 million in 2018). In contrast, more pulmonary disease, lung cancer, and other age-related However, specialized biopharma companies are Alzheimer's, according to the latest data Japan is the only declining market among outperforming these large cap companies from 2016.


Related search queries